Nuwellis 10-K Reveals $8.27M Full-Year Revenue, $(25.39) Per Share Loss
Summary
Nuwellis, Inc. has filed its annual 10-K report, revealing full fiscal year 2025 net sales of $8.27 million, a 5.4% decrease year-over-year, and a substantial basic and diluted loss of $(25.39) per share. The company also reported a net loss of $(17.521) million and a decline in gross margin to 62.0%. These full-year results provide a comprehensive view following yesterday's Q4 2025 earnings reports. For a company with a very small market capitalization, the revenue decline and significant per-share loss highlight severe financial challenges and operational headwinds. The report also detailed strategic shifts, including exiting select international operations and terminating the REVERSE-HF clinical trial to reallocate resources. Traders will closely watch the effectiveness of these strategic changes and the company's ongoing capital management efforts to address its financial performance.
At the time of this announcement, NUWE was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $1.20 to $53.34. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.